BioPharma Dive - Latest News

Tempest seeks strategic alternatives as cash runs out for Phase 3 trial

Amid a funding drought for startups, the company is looking for a deal that can advance its liver cancer drug.

Apr 10, 2025 - 16:56
 0
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial

Amid a funding drought for startups, the company is looking for a deal that can advance its liver cancer drug.

Read More

Tags:

Previous Article

Duetto Purchases HotStats to Boost Expansion in the Hospitality Software Sector

Next Article

Reviews: Waterloo Heads to Flavortown, Florence By Mills, OHMG

Related Posts

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

‘It’s not for the faint of heart.’ How 3 CEOs took thei...

Feb 14, 2025  0

Eli Lilly’s earnings, shares lifted by obesity drug sales

Eli Lilly’s earnings, shares lifted by obesity drug sales

Feb 9, 2025  0

Walgreens to be acquired in $10B take-private deal

Walgreens to be acquired in $10B take-private deal

Mar 7, 2025  0